iX Biopharma Ltd.
Research iX Biopharma Ltd. (42C.SI) on Bullrun: market cap SGD 575.40M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker42C.SI
- ExchangeSGX
- CountrySingapore
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySGD
- Market capSGD 575.40M
- Financial periodQ2 2026
- RevenueSGD 2.09M
- Net income-SGD 5.02M
- Free cash flow-SGD 2.72M
- Gross margin48.4%
Valuation Snapshot
latest market cap is SGD 575.40M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | SGD 575.40M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SGD.
About iX Biopharma Ltd.
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, Australia and internationally. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is iX Biopharma Ltd.'s market cap?
iX Biopharma Ltd.'s market capitalization is SGD 575.40M.
What does iX Biopharma Ltd. do?
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, Australia and internationally. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, insomnia and other conditions.